Condition: Triple Negative Breast Cancer · HER2-negative Breast Cancer · Non Small Cell Lung Cancer · Sponsor: Dren Bio
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
This description comes directly from the study's public registry record.
Dren Bio Central Contact · 415-737-5277 · DR-0202-ONC-001_inquiries@drenbio.com
Always discuss trial participation with your own doctor first.
| Dren Investigational Site | Denver, Colorado, United States | Recruiting |
| Dren Investigational Site | Orlando, Florida, United States | Recruiting |
| Dren Investigational Site | Sarasota, Florida, United States | Recruiting |
| Dren Investigational Site | Huntersville, North Carolina, United States | Recruiting |
| Dren Investigational Site | Oklahoma City, Oklahoma, United States | Recruiting |
| Dren Investigational Site | Greenville, South Carolina, United States | Recruiting |
| Dren Investigational Site | Austin, Texas, United States | Recruiting |
| Dren Investigational Site | Dallas, Texas, United States | Recruiting |
| Dren Investigational Site | San Antonio, Texas, United States | Recruiting |
| Dren Investigational Site | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06999187